BACKGROUND: Fibroblast growth factor 23 (FGF23), uncarboxylated matrix Gla protein (ucMGP), and fetuin-A are regulators of mineral metabolism and inhibitors of vascular calcification. Whether circulating levels of each are associated with cardiovascular disease (CVD) events or mortality in populations without end-stage renal disease is unknown. OBJECTIVE: To evaluate the associations of FGF23, ucMGP, and fetuin-A with mortality and CVD events. DESIGN: Observational study. SETTING: 12 outpatient clinics in the San Francisco Bay area. PATIENTS: 833 outpatients with stable coronary artery disease (CAD), recruited from 11 September 2000 to 20 December 2002. MEASUREMENTS: Fibroblast growth factor 23, ucMGP, and fetuin-A concentrations were measured at baseline. Participants were followed until 1 December 2008 for mortality and CVD events. RESULTS: During a median follow-up of 6.0 years, 220 participants died and 182 had CVD events. Compared with participants with FGF-23 levels in the lowest tertile, those in the highest tertile had 2-fold greater risk for mortality (hazard ratio [HR], 2.15 [95% CI, 1.43 to 3.24]) and CVD events (HR, 1.83 [CI, 1.15 to 2.91]) after adjustment for traditional CVD risk factors, C-reactive protein levels, and kidney function. The highest ucMGP tertile was associated with lower mortality risk (HR, 0.48 [CI, 0.31 to 0.75]) and showed a nonsignificant trend toward lower CVD event risk by tertile analysis (HR, 0.65 [CI, 0.40 to 1.05])-an association that was significant when modeled continuously (P = 0.029). No significant association of fetuin-A with mortality (HR, 0.84 [CI, 0.55 to 1.27]) or CVD events (HR, 0.99 [CI, 0.64 to 1.55]) was observed. LIMITATION: Participants had prevalent CAD. CONCLUSION: In outpatients with stable CAD, higher FGF23 and lower ucMGP levels are independently associated with mortality and CVD events. PRIMARY FUNDING SOURCE: American Heart Association.
BACKGROUND:Fibroblast growth factor 23 (FGF23), uncarboxylated matrix Gla protein (ucMGP), and fetuin-A are regulators of mineral metabolism and inhibitors of vascular calcification. Whether circulating levels of each are associated with cardiovascular disease (CVD) events or mortality in populations without end-stage renal disease is unknown. OBJECTIVE: To evaluate the associations of FGF23, ucMGP, and fetuin-A with mortality and CVD events. DESIGN: Observational study. SETTING: 12 outpatient clinics in the San Francisco Bay area. PATIENTS: 833 outpatients with stable coronary artery disease (CAD), recruited from 11 September 2000 to 20 December 2002. MEASUREMENTS: Fibroblast growth factor 23, ucMGP, and fetuin-A concentrations were measured at baseline. Participants were followed until 1 December 2008 for mortality and CVD events. RESULTS: During a median follow-up of 6.0 years, 220 participants died and 182 had CVD events. Compared with participants with FGF-23 levels in the lowest tertile, those in the highest tertile had 2-fold greater risk for mortality (hazard ratio [HR], 2.15 [95% CI, 1.43 to 3.24]) and CVD events (HR, 1.83 [CI, 1.15 to 2.91]) after adjustment for traditional CVD risk factors, C-reactive protein levels, and kidney function. The highest ucMGP tertile was associated with lower mortality risk (HR, 0.48 [CI, 0.31 to 0.75]) and showed a nonsignificant trend toward lower CVD event risk by tertile analysis (HR, 0.65 [CI, 0.40 to 1.05])-an association that was significant when modeled continuously (P = 0.029). No significant association of fetuin-A with mortality (HR, 0.84 [CI, 0.55 to 1.27]) or CVD events (HR, 0.99 [CI, 0.64 to 1.55]) was observed. LIMITATION: Participants had prevalent CAD. CONCLUSION: In outpatients with stable CAD, higher FGF23 and lower ucMGP levels are independently associated with mortality and CVD events. PRIMARY FUNDING SOURCE: American Heart Association.
Authors: Joanne L Reynolds; Alexis J Joannides; Jeremy N Skepper; Rosamund McNair; Leon J Schurgers; Diane Proudfoot; Willi Jahnen-Dechent; Peter L Weissberg; Catherine M Shanahan Journal: J Am Soc Nephrol Date: 2004-11 Impact factor: 10.121
Authors: Kumar Sharma; Joachim H Ix; Anna V Mathew; Monique Cho; Axel Pflueger; Stephen R Dunn; Barbara Francos; Shoba Sharma; Bonita Falkner; Tracy A McGowan; Michael Donohue; Satish Ramachandrarao; Ronghui Xu; Fernando C Fervenza; Jeffrey B Kopp Journal: J Am Soc Nephrol Date: 2011-04-21 Impact factor: 10.121
Authors: Christian Faul; Ansel P Amaral; Behzad Oskouei; Ming-Chang Hu; Alexis Sloan; Tamara Isakova; Orlando M Gutiérrez; Robier Aguillon-Prada; Joy Lincoln; Joshua M Hare; Peter Mundel; Azorides Morales; Julia Scialla; Michael Fischer; Elsayed Z Soliman; Jing Chen; Alan S Go; Sylvia E Rosas; Lisa Nessel; Raymond R Townsend; Harold I Feldman; Martin St John Sutton; Akinlolu Ojo; Crystal Gadegbeku; Giovana Seno Di Marco; Stefan Reuter; Dominik Kentrup; Klaus Tiemann; Marcus Brand; Joseph A Hill; Orson W Moe; Makoto Kuro-O; John W Kusek; Martin G Keane; Myles Wolf Journal: J Clin Invest Date: 2011-10-10 Impact factor: 14.808
Authors: Sherri-Ann M Burnett-Bowie; Benjamin Z Leder; Maria P Henao; Chantel M Baldwin; Douglas L Hayden; Joel S Finkelstein Journal: Clin J Am Soc Nephrol Date: 2012-02-02 Impact factor: 8.237
Authors: Julia M Hum; Linda M O'Bryan; Arun K Tatiparthi; Erica L Clinkenbeard; Pu Ni; Martin S Cramer; Manoj Bhaskaran; Robert L Johnson; Jonathan M Wilson; Rosamund C Smith; Kenneth E White Journal: J Appl Physiol (1985) Date: 2019-01-03
Authors: Pranav S Garimella; Joachim H Ix; Ronit Katz; Michel B Chonchol; Bryan R Kestenbaum; Ian H de Boer; David S Siscovick; Shani Shastri; Jade S Hiramoto; Michael G Shlipak; Mark J Sarnak Journal: Atherosclerosis Date: 2014-01-04 Impact factor: 5.162
Authors: Rupal Mehta; Gui Shuang Ying; Samuel Houston; Tamara Isakova; Lisa Nessel; Akinlolu Ojo; Alan Go; Jim Lash; John Kusek; Juan Grunwald; Myles Wolf Journal: Nephrol Dial Transplant Date: 2015-04-24 Impact factor: 5.992